{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:52:32Z","timestamp":1791550352292,"version":"4.3.4"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41574-026-01282-5","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:00:51Z","timestamp":1785168051000},"page":"646-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose matters: haploinsufficiency in osteogenesis imperfecta"],"prefix":"10.1038","volume":"22","author":[{"given":"Anastasia","family":"Sclocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2307-8180","authenticated-orcid":false,"given":"Wenya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1732-6618","authenticated-orcid":false,"given":"Laura","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8713-5909","authenticated-orcid":false,"given":"Leander","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5399-676X","authenticated-orcid":false,"given":"Elisabeth M. W.","family":"Eekhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7890-4411","authenticated-orcid":false,"given":"Dimitra","family":"Micha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiia","family":"Zhytnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"1282_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/biom13020281","volume":"13","author":"S Storoni","year":"2023","unstructured":"Storoni, S. et al. From genetics to clinical implications: a study of 675 Dutch osteogenesis imperfecta patients. Biomolecules 13, 281 (2023).","journal-title":"Biomolecules"},{"key":"1282_CR2","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","volume":"23","author":"K Lindahl","year":"2015","unstructured":"Lindahl, K. et al. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur. J. Hum. Genet. 23, 1042\u20131050 (2015).","journal-title":"Eur. J. Hum. Genet."},{"key":"1282_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03345-0","volume":"19","author":"I Westerheim","year":"2024","unstructured":"Westerheim, I., Cormier-Daire, V., Gilbert, S., O\u2019Malley, S. & Keen, R. Osteogenesis imperfecta: a study of the patient journey in 13 European countries. Orphanet J. Rare Dis. 19, 331 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"1282_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00223-024-01248-7","volume":"115","author":"DO Sillence","year":"2024","unstructured":"Sillence, D. O. A dyadic nosology for osteogenesis imperfecta and bone fragility syndromes 2024. Calcif. Tissue Int. 115, 873\u2013890 (2024).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/nar\/25.1.181","volume":"25","author":"R Dalgleish","year":"1997","unstructured":"Dalgleish, R. The human type I collagen mutation database. Nucleic Acids Res. 25, 181\u2013187 (1997).","journal-title":"Nucleic Acids Res."},{"key":"1282_CR6","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00198-016-3709-1","volume":"27","author":"G Bardai","year":"2016","unstructured":"Bardai, G., Moffatt, P., Glorieux, F. H. & Rauch, F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteoporos. Int. 27, 3607\u20133613 (2016).","journal-title":"Osteoporos. Int."},{"key":"1282_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence, D. O., Senn, A. & Danks, D. M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16, 101\u2013116 (1979).","journal-title":"J. Med. Genet."},{"key":"1282_CR8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.nurpra.2018.03.005","volume":"14","author":"RL Tatlock","year":"2018","unstructured":"Tatlock, R. L., Edwards, N., Imel, E. A. & Foli, K. J. Osteogenesis imperfecta type I: recognition in primary care. J. Nurse Pract. 14, 470\u2013476 (2018).","journal-title":"J. Nurse Pract."},{"key":"1282_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03126-9","volume":"19","author":"I Westerheim","year":"2024","unstructured":"Westerheim, I. et al. The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers. Orphanet J. Rare Dis. 19, 128 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"1282_CR10","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10782","volume":"7","author":"KK Joshi","year":"2023","unstructured":"Joshi, K. K., Siafarikas, A. & Prince, R. The natural history of symptomatic fractures in children and adolescents with osteogenesis imperfecta type 1: a cohort study from Western Australia. JBMR Plus 7, e10782 (2023).","journal-title":"JBMR Plus"},{"key":"1282_CR11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/ard.59.3.166","volume":"59","author":"AA Deodhar","year":"2000","unstructured":"Deodhar, A. A. & Woolf, A. D. Fragile without fractures. Ann. Rheum. Dis. 59, 166\u2013171 (2000).","journal-title":"Ann. Rheum. Dis."},{"key":"1282_CR12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","volume":"310","author":"CR Paterson","year":"1984","unstructured":"Paterson, C. R., McAllion, S. & Stellman, J. L. Osteogenesis imperfecta after the menopause. N. Engl. J. Med. 310, 1694\u20131696 (1984).","journal-title":"N. Engl. J. Med."},{"key":"1282_CR13","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.1942","volume":"28","author":"IM Ben Amor","year":"2013","unstructured":"Ben Amor, I. M., Roughley, P., Glorieux, F. H. & Rauch, F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J. Bone Miner. Res. 28, 2001\u20132007 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cge.12409","volume":"87","author":"RM Patel","year":"2015","unstructured":"Patel, R. M. et al. A cross-sectional multicenter study of osteogenesis imperfecta in North America \u2013 results from the linked clinical research centers. Clin. Genet. 87, 133\u2013140 (2015).","journal-title":"Clin. Genet."},{"key":"1282_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00256-012-1512-4","volume":"42","author":"R Kocijan","year":"2013","unstructured":"Kocijan, R. et al. Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta. Skelet. Radiol. 42, 187\u2013194 (2013).","journal-title":"Skelet. Radiol."},{"key":"1282_CR16","doi-asserted-by":"crossref","first-page":"115915","DOI":"10.1016\/j.bone.2021.115915","volume":"147","author":"JE Schanda","year":"2021","unstructured":"Schanda, J. E. et al. Analysis of bone architecture using fractal-based TX-AnalyzerTM in adult patients with osteogenesis imperfecta. Bone 147, 115915 (2021).","journal-title":"Bone"},{"key":"1282_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","volume":"87","author":"JR Shapiro","year":"2010","unstructured":"Shapiro, J. R., Thompson, C. B., Wu, Y., Nunes, M. & Gillen, C. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif. Tissue Int. 87, 120\u2013129 (2010).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","volume":"6","author":"LL Wekre","year":"2011","unstructured":"Wekre, L. L., Eriksen, E. F. & Falch, J. A. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta. Arch. Osteoporos. 6, 31\u201338 (2011).","journal-title":"Arch. Osteoporos."},{"key":"1282_CR19","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s40618-024-02380-9","volume":"47","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta. J. Endocrinol. Invest. 47, 2785\u20132795 (2024).","journal-title":"J. Endocrinol. Invest."},{"key":"1282_CR20","doi-asserted-by":"crossref","first-page":"110048","DOI":"10.1016\/j.exer.2024.110048","volume":"247","author":"SJE Verdonk","year":"2024","unstructured":"Verdonk, S. J. E. et al. Polarization-sensitive optical coherence tomography and scleral collagen fiber orientation in osteogenesis imperfecta. Exp. Eye Res. 247, 110048 (2024).","journal-title":"Exp. Eye Res."},{"key":"1282_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ajmg.1320450207","volume":"45","author":"D Sillence","year":"1993","unstructured":"Sillence, D., Butler, B., Latham, M. & Barlow, K. Natural history of blue sclerae in osteogenesis imperfecta. Am. J. Med. Genet. 45, 183\u2013186 (1993).","journal-title":"Am. J. Med. Genet."},{"key":"1282_CR22","doi-asserted-by":"crossref","first-page":"116249","DOI":"10.1016\/j.bone.2021.116249","volume":"154","author":"ML Lyster","year":"2022","unstructured":"Lyster, M. L., Hald, J. D., Rasmussen, M. L., Grauslund, J. & Folkestad, L. Risk of eye diseases in osteogenesis imperfecta \u2013 a nationwide, register-based cohort study. Bone 154, 116249 (2022).","journal-title":"Bone"},{"key":"1282_CR23","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s00198-018-4663-x","volume":"29","author":"JD Hald","year":"2018","unstructured":"Hald, J. D. et al. Osteogenesis imperfecta and the teeth, eyes, and ears\u2014a study of non-skeletal phenotypes in adults. Osteoporos. Int. 29, 2781\u20132789 (2018).","journal-title":"Osteoporos. Int."},{"key":"1282_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00405-024-08983-5","volume":"282","author":"A Felicio-Briegel","year":"2025","unstructured":"Felicio-Briegel, A. et al. Hearing impairment amongst people with osteogenesis imperfecta in Germany. Eur. Arch. Otorhinolaryngol. 282, 765\u2013771 (2025).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"1282_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00223-024-01293-2","volume":"115","author":"L Ventura","year":"2024","unstructured":"Ventura, L. et al. Dental abnormalities in osteogenesis imperfecta: a systematic review. Calcif. Tissue Int. 115, 461\u2013479 (2024).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR26","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/07853890.2021.1980819","volume":"53","author":"S Storoni","year":"2021","unstructured":"Storoni, S. et al. Pathophysiology of respiratory failure in patients with osteogenesis imperfecta: a systematic review. Ann. Med. 53, 1676\u20131687 (2021).","journal-title":"Ann. Med."},{"key":"1282_CR27","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/ajmg.a.62658","volume":"188","author":"HM LoTurco","year":"2022","unstructured":"LoTurco, H. M., Carter, E. M., McInerney, D. E. & Raggio, C. L. Patient-reported prevalence of gastrointestinal issues in the adult skeletal dysplasia population with a concentration on osteogenesis imperfecta. Am. J. Med. Genet. A 188, 1435\u20131442 (2022).","journal-title":"Am. J. Med. Genet. A"},{"key":"1282_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00223-024-01311-3","volume":"116","author":"CK Anderesen","year":"2025","unstructured":"Anderesen, C. K., Al-Najami, I., Liu, W., Orwoll, E. & Folkestad, L. Risk of gastrointestinal diseases in osteogenesis imperfecta: a nationwide, register-based cohort study. Calcif. Tissue Int. 116, 15 (2025).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jbmr\/zjae197","volume":"40","author":"L Folkestad","year":"2025","unstructured":"Folkestad, L. et al. Cardiovascular disease in adults with osteogenesis imperfecta: clinical characteristics, care recommendations, and research priorities identified using a modified Delphi technique. J. Bone Miner. Res. 40, 211\u2013221 (2025).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00223-023-01171-3","volume":"114","author":"SJE Verdonk","year":"2024","unstructured":"Verdonk, S. J. E. et al. Is osteogenesis imperfecta associated with cardiovascular abnormalities? A systematic review of the literature. Calcif. Tissue Int. 114, 210\u2013221 (2024).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03054-8","volume":"19","author":"K Gooijer","year":"2024","unstructured":"Gooijer, K. et al. Bleeding assessment in a large cohort of patients with osteogenesis imperfecta. Orphanet J. Rare Dis. 19, 61 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"1282_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.26502\/fccm.92920302","volume":"07","author":"D Singh","year":"2023","unstructured":"Singh, D., Rai, V. & Agrawal, D. K. Regulation of collagen I and collagen III in tissue injury and regeneration. Cardiol. Cardiovasc. Med. 07, 5\u201316 (2023).","journal-title":"Cardiol. Cardiovasc. Med."},{"key":"1282_CR33","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.apmr.2017.03.018","volume":"98","author":"A Pouliot-Laforte","year":"2017","unstructured":"Pouliot-Laforte, A., Lemay, M., Rauch, F. & Veilleux, L.-N. Static postural control in youth with osteogenesis imperfecta type I. Arch. Phys. Med. Rehabil. 98, 1948\u20131954 (2017).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"1282_CR34","doi-asserted-by":"crossref","first-page":"ziaf099","DOI":"10.1093\/jbmrpl\/ziaf099","volume":"9","author":"A Ireland","year":"2025","unstructured":"Ireland, A. et al. Muscle impairments in osteogenesis imperfecta: a narrative review. JBMR Plus 9, ziaf099 (2025).","journal-title":"JBMR Plus"},{"key":"1282_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-428","volume":"15","author":"H Arponen","year":"2014","unstructured":"Arponen, H., M\u00e4kitie, O. & Waltimo-Sir\u00e9n, J. Association between joint hypermobility, scoliosis, and cranial base anomalies in paediatric osteogenesis imperfecta patients: a retrospective cross-sectional study. BMC Musculoskelet. Disord. 15, 428 (2014).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1282_CR36","doi-asserted-by":"crossref","first-page":"ziaf076","DOI":"10.1093\/jbmrpl\/ziaf076","volume":"9","author":"JY Moon","year":"2025","unstructured":"Moon, J. Y. et al. Pain and physical function affecting quality of life in patients with osteogenesis imperfecta, X-linked hypophosphatemia, and hypermobile Ehlers-Danlos syndrome. JBMR Plus 9, ziaf076 (2025).","journal-title":"JBMR Plus"},{"key":"1282_CR37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ajmg.a.63009","volume":"191","author":"M Rodriguez Celin","year":"2023","unstructured":"Rodriguez Celin, M. et al. A multicenter study to evaluate pain characteristics in osteogenesis imperfecta. Am. J. Med. Genet. A 191, 160\u2013172 (2023).","journal-title":"Am. J. Med. Genet. A"},{"key":"1282_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-20555-0","volume":"24","author":"T van Welzenis","year":"2024","unstructured":"van Welzenis, T. et al. The IMPACT survey: the humanistic impact of osteogenesis imperfecta in adults. BMC Public Health 24, 3318 (2024).","journal-title":"BMC Public Health"},{"key":"1282_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02728-z","volume":"18","author":"S Wehrli","year":"2023","unstructured":"Wehrli, S., Rohrbach, M. & Landolt, M. A. Quality of life of pediatric and adult individuals with osteogenesis imperfecta: a meta-analysis. Orphanet J. Rare Dis. 18, 123 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1282_CR40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s11136-016-1247-0","volume":"25","author":"A Tsimicalis","year":"2016","unstructured":"Tsimicalis, A. et al. The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review. Qual. Life Res. 25, 1877\u20131896 (2016).","journal-title":"Qual. Life Res."},{"key":"1282_CR41","doi-asserted-by":"crossref","first-page":"100362","DOI":"10.1016\/j.ajogmf.2021.100362","volume":"3","author":"R Rao","year":"2021","unstructured":"Rao, R. et al. Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes. Am. J. Obstet. Gynecol. MFM 3, 100362 (2021).","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"1282_CR42","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/jp.2016.111","volume":"36","author":"J Ruiter-Ligeti","year":"2016","unstructured":"Ruiter-Ligeti, J., Czuzoj-Shulman, N., Spence, A. R., Tulandi, T. & Abenhaim, H. A. Pregnancy outcomes in women with osteogenesis imperfecta: a retrospective cohort study. J. Perinatol. 36, 828\u2013831 (2016).","journal-title":"J. Perinatol."},{"key":"1282_CR43","doi-asserted-by":"crossref","first-page":"117202","DOI":"10.1016\/j.bone.2024.117202","volume":"187","author":"EK Lykking","year":"2024","unstructured":"Lykking, E. K., Damkier, P., Kammerlander, H., Broe, A. & Folkestad, L. Pregnancy complications and birth outcome in patients with osteogenesis imperfecta \u2013 a population-based register study. Bone 187, 117202 (2024).","journal-title":"Bone"},{"key":"1282_CR44","volume":"7","author":"L Zhytnik","year":"2019","unstructured":"Zhytnik, L. et al. De novo and inherited pathogenic variants in collagen-related osteogenesis imperfecta. Mol. Genet. Genom. Med. 7, e559 (2019).","journal-title":"Mol. Genet. Genom. Med."},{"key":"1282_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01404-w","volume":"15","author":"L Zhytnik","year":"2020","unstructured":"Zhytnik, L. et al. Reproductive options for families at risk of osteogenesis imperfecta: a review. Orphanet J. Rare Dis. 15, 128 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"1282_CR46","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3389\/fgene.2019.00979","volume":"10","author":"L Li","year":"2019","unstructured":"Li, L. et al. Validation and classification of atypical splicing variants associated with osteogenesis imperfecta. Front. Genet. 10, 979 (2019).","journal-title":"Front. Genet."},{"key":"1282_CR47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/jmg-2022-108763","volume":"60","author":"B Tuysuz","year":"2023","unstructured":"Tuysuz, B. et al. Biallelic frameshift variants in PHLDB1 cause mild-type osteogenesis imperfecta with regressive spondylometaphyseal changes. J. Med. Genet. 60, 819\u2013826 (2023).","journal-title":"J. Med. Genet."},{"key":"1282_CR48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmg-2025-110807","volume":"62","author":"DO Sillence","year":"2025","unstructured":"Sillence, D. O. Six at sixty. Commentary on osteogenesis imperfecta 1975\u20132025. J. Med. Genet. 62, 422\u2013426 (2025).","journal-title":"J. Med. Genet."},{"key":"1282_CR49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/jmg.27.9.545","volume":"27","author":"WG Cole","year":"1990","unstructured":"Cole, W. G., Campbell, P. E., Rogers, J. G. & Bateman, J. F. The clinical features of osteogenesis imperfecta resulting from a non-functional carboxy terminal pro alpha 1(I) propeptide of type I procollagen and a severe deficiency of normal type I collagen in tissues. J. Med. Genet. 27, 545\u2013551 (1990).","journal-title":"J. Med. Genet."},{"key":"1282_CR50","first-page":"2551","volume":"126","author":"Y Fang","year":"2013","unstructured":"Fang, Y., Bateman, J. F., Mercer, J. F. & Lamand\u00e9, S. R. Nonsense-mediated mRNA decay of collagen \u2014 emerging complexity in RNA surveillance mechanisms. J. Cell Sci. 126, 2551\u20132560 (2013).","journal-title":"J. Cell Sci."},{"key":"1282_CR51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/humu.22812","volume":"36","author":"J Schleit","year":"2015","unstructured":"Schleit, J. et al. Molecular outcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the pro\u03b11(I) chains of type I procollagen. Hum. Mutat. 36, 728\u2013739 (2015).","journal-title":"Hum. Mutat."},{"key":"1282_CR52","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/GIM.0b013e3181f01617","volume":"12","author":"FS van Dijk","year":"2010","unstructured":"van Dijk, F. S. et al. Complete COL1A1 allele deletions in osteogenesis imperfecta. Genet. Med. 12, 736\u2013741 (2010).","journal-title":"Genet. Med."},{"key":"1282_CR53","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00223-015-0066-6","volume":"98","author":"G Bardai","year":"2016","unstructured":"Bardai, G. et al. Osteogenesis imperfecta type I caused by COL1A1 deletions. Calcif. Tissue Int. 98, 76\u201384 (2016).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR54","first-page":"638","volume":"55","author":"MC Willing","year":"1994","unstructured":"Willing, M. C. et al. Osteogenesis imperfecta type 1: molecular heterogeneity for COL I A I null alleles of type I collagen. Am. J. Hum. Genet. 55, 638\u2013647 (1994).","journal-title":"Am. J. Hum. Genet."},{"key":"1282_CR55","first-page":"975","volume":"46","author":"RJ Wenstrup","year":"1990","unstructured":"Wenstrup, R. J., Willing, M. C., Starmant, B. J. & Byers, P. H. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. Am. J. Hum. Genet. 46, 975\u2013982 (1990).","journal-title":"Am. J. Hum. Genet."},{"key":"1282_CR56","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00439-021-02302-2","volume":"140","author":"L Claeys","year":"2021","unstructured":"Claeys, L. et al. Collagen transport and related pathways in osteogenesis imperfecta. Hum. Genet. 140, 1121\u20131141 (2021).","journal-title":"Hum. Genet."},{"key":"1282_CR57","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2019.09.081","volume":"521","author":"D Micha","year":"2020","unstructured":"Micha, D., Pals, G., Smit, T. H. & Ghazanfari, S. An in vitro model to evaluate the properties of matrices produced by fibroblasts from osteogenesis imperfecta and Ehlers-Danlos syndrome patients. Biochem. Biophys. Res. Commun. 521, 310\u2013317 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1282_CR58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.bi.64.070195.002155","volume":"64","author":"DJ Prockop","year":"1995","unstructured":"Prockop, D. J. & Kivirikko, K. I. COLLAGENS: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. 64, 403\u2013434 (1995).","journal-title":"Annu. Rev. Biochem."},{"key":"1282_CR59","doi-asserted-by":"crossref","first-page":"1145125","DOI":"10.3389\/fendo.2023.1145125","volume":"14","author":"L Claeys","year":"2023","unstructured":"Claeys, L. et al. Exploration of the skeletal phenotype of the Col1a1+\/Mov13 mouse model for haploinsufficient osteogenesis imperfecta type 1. Front. Endocrinol. 14, 1145125 (2023).","journal-title":"Front. Endocrinol."},{"key":"1282_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf138","author":"L Zhytnik","year":"2025","unstructured":"Zhytnik, L. et al. New lens on congenital mild bone fragility: a novel Col1a1 knockout mouse model for osteogenesis imperfecta type 1. J. Bone Miner. Res. https:\/\/doi.org\/10.1093\/jbmr\/zjaf138 (2025).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1095\/biolreprod.115.138115","volume":"94","author":"Y Zheng","year":"2016","unstructured":"Zheng, Y. et al. Epigenetic modulation of collagen 1A1: therapeutic implications in fibrosis and endometriosis1. Biol. Reprod. 94, 87 (2016).","journal-title":"Biol. Reprod."},{"key":"1282_CR62","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s002239900719","volume":"65","author":"P Sarathchandra","year":"1999","unstructured":"Sarathchandra, P., Pope, F. M. & Ali, S. Y. Morphometric analysis of type I collagen fibrils in the osteoid of osteogenesis imperfecta. Calcif. Tissue Int. 65, 390\u2013395 (1999).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00003086-198403000-00032","volume":"183","author":"CJ Jones","year":"1984","unstructured":"Jones, C. J., Cummings, C., Ball, J. & Beighton, P. Collagen defect of bone in osteogenesis imperfecta (Type I). An electron microscopic study. Clin. Orthop. Relat. Res. 183, 208\u2013214 (1984).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"1282_CR64","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0968-4328(00)00043-3","volume":"32","author":"DE Birk","year":"2001","unstructured":"Birk, D. E. Type V collagen: heterotypic type I\/V collagen interactions in the regulation of fibril assembly. Micron 32, 223\u2013237 (2001).","journal-title":"Micron"},{"key":"1282_CR65","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/cts.12783","volume":"13","author":"L Zhytnik","year":"2020","unstructured":"Zhytnik, L. et al. Inter- and intrafamilial phenotypic variability in individuals with collagen-related osteogenesis imperfecta. Clin. Transl. Sci. 13, 960\u2013971 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"1282_CR66","doi-asserted-by":"crossref","first-page":"dmm049398","DOI":"10.1242\/dmm.049398","volume":"15","author":"N Garibaldi","year":"2022","unstructured":"Garibaldi, N. et al. Dissecting the phenotypic variability of osteogenesis imperfecta. Dis. Model. Mech. 15, dmm049398 (2022).","journal-title":"Dis. Model. Mech."},{"key":"1282_CR67","doi-asserted-by":"crossref","first-page":"116706","DOI":"10.1016\/j.bone.2023.116706","volume":"170","author":"C Shao","year":"2023","unstructured":"Shao, C. et al. DNA methyltransferases inhibitor azacitidine improves the skeletal phenotype of mild osteogenesis imperfecta by reversing the impaired osteogenesis and excessive osteoclastogenesis. Bone 170, 116706 (2023).","journal-title":"Bone"},{"key":"1282_CR68","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/jbmr.4912","volume":"38","author":"A Mercier-Guery","year":"2023","unstructured":"Mercier-Guery, A. et al. Dysregulation of MicroRNAs in adult osteogenesis imperfecta: the miROI study. J. Bone Miner. Res. 38, 1665\u20131678 (2023).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR69","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/jbmr.5650070809","volume":"7","author":"NS Fedarko","year":"1992","unstructured":"Fedarko, N. S., Moerike, M., Brenner, R., Robey, P. G. & Vetter, U. Extracellular matrix formation by osteoblasts from patients with osteogenesis imperfecta. J. Bone Miner. Res. 7, 921\u2013930 (1992).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR70","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH704>3.0.CO;2-U","volume":"192","author":"P Sarathchandra","year":"2000","unstructured":"Sarathchandra, P., Pope, F. M., Kayser, M. V. & Ali, S. Y. A light and electron microscopic study of osteogenesis imperfecta bone samples, with reference to collagen chemistry and clinical phenotype. J. Pathol. 192, 385\u2013395 (2000).","journal-title":"J. Pathol."},{"key":"1282_CR71","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jbmr.5650100718","volume":"10","author":"NS Fedarko","year":"1995","unstructured":"Fedarko, N. S., Robey, P. G. & Vetter, U. K. Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J. Bone Miner. Res. 10, 1122\u20131129 (1995).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10354-021-00818-w","volume":"171","author":"M M\u00e4hr","year":"2021","unstructured":"M\u00e4hr, M. et al. Bone properties in osteogenesis imperfecta: what can we learn from a bone biopsy beyond histology? Wien. Med. Wochenschr. 171, 111\u2013119 (2021).","journal-title":"Wien. Med. Wochenschr."},{"key":"1282_CR73","doi-asserted-by":"crossref","first-page":"116580","DOI":"10.1016\/j.bone.2022.116580","volume":"166","author":"BM Misof","year":"2023","unstructured":"Misof, B. M. et al. Accelerated mineralization kinetics in children with osteogenesis imperfecta type 1. Bone 166, 116580 (2023).","journal-title":"Bone"},{"key":"1282_CR74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","volume":"26","author":"F Rauch","year":"2000","unstructured":"Rauch, F., Travers, R., Parfitt, A. M. & Glorieux, F. H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26, 581\u2013589 (2000).","journal-title":"Bone"},{"key":"1282_CR75","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/BF02556213","volume":"49","author":"U Vetter","year":"1991","unstructured":"Vetter, U., Eanes, E. D., Kopp, J. B., Termine, J. D. & Robey, P. G. Changes in apatite crystal size in bones of patients with osteogenesis imperfecta. Calcif. Tissue Int. 49, 248\u2013250 (1991).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bone.2014.04.030","volume":"65","author":"L Imbert","year":"2014","unstructured":"Imbert, L., Aur\u00e9gan, J.-C., Pernelle, K. & Hoc, T. Mechanical and mineral properties of osteogenesis imperfecta human bones at the tissue level. Bone 65, 18\u201324 (2014).","journal-title":"Bone"},{"key":"1282_CR77","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.1592","volume":"27","author":"L Folkestad","year":"2012","unstructured":"Folkestad, L. et al. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. J. Bone Miner. Res. 27, 1405\u20131412 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR78","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00198-015-3156-4","volume":"26","author":"R Kocijan","year":"2015","unstructured":"Kocijan, R. et al. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta. Osteoporos. Int. 26, 2431\u20132440 (2015).","journal-title":"Osteoporos. Int."},{"key":"1282_CR79","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/03008209509010822","volume":"31","author":"A Vignery","year":"1995","unstructured":"Vignery, A. Bone cell defects in osteogenesis imperfecta. Connect. Tissue Res. 31, 275\u2013278 (1995).","journal-title":"Connect. Tissue Res."},{"key":"1282_CR80","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s007740200025","volume":"20","author":"J Iwamoto","year":"2002","unstructured":"Iwamoto, J., Takeda, T. & Ichimura, S. Increased bone resorption with decreased activity and increased recruitment of osteoblasts in osteogenesis imperfecta type I. J. Bone Miner. Metab. 20, 174\u2013179 (2002).","journal-title":"J. Bone Miner. Metab."},{"key":"1282_CR81","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.3390\/ijms22094508","volume":"22","author":"M M\u00e4hr","year":"2021","unstructured":"M\u00e4hr, M. et al. Increased osteocyte lacunae density in the hypermineralized bone matrix of children with osteogenesis imperfecta type I. Int. J. Mol. Sci. 22, 4508 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1282_CR82","doi-asserted-by":"crossref","first-page":"ziae112","DOI":"10.1093\/jbmrpl\/ziae112","volume":"8","author":"S Aksornthong","year":"2024","unstructured":"Aksornthong, S., Patel, P. & Komarova, S. V. Osteoclast indices in osteogenesis imperfecta: systematic review and meta-analysis. JBMR Plus 8, ziae112 (2024).","journal-title":"JBMR Plus"},{"key":"1282_CR83","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/jbmr.4326","volume":"36","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Modification of COL1A1 in autologous adipose tissue-derived progenitor cells rescues the bone phenotype in a mouse model of osteogenesis imperfecta. J. Bone Miner. Res. 36, 1521\u20131534 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-15-45","volume":"15","author":"CM Kaneto","year":"2014","unstructured":"Kaneto, C. M. et al. COL1A1 and miR-29b show lower expression levels during osteoblast differentiation of bone marrow stromal cells from osteogenesis imperfecta patients. BMC Med. Genet. 15, 45 (2014).","journal-title":"BMC Med. Genet."},{"key":"1282_CR85","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bone.2019.07.021","volume":"127","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I. Bone 127, 646\u2013655 (2019).","journal-title":"Bone"},{"key":"1282_CR86","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jbmr\/zjaf068","volume":"40","author":"E Busschers","year":"2025","unstructured":"Busschers, E. et al. Anti-transforming growth factor-\u03b2 treatment shows increased bone mass and strength in a novel mouse model for osteogenesis imperfecta type I. J. Bone Miner. Res. 40, 881\u2013890 (2025).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR87","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000104789","volume":"12","author":"KM Stankovic","year":"2007","unstructured":"Stankovic, K. M. et al. Studies of otic capsule morphology and gene expression in the Mov13 mouse \u2013 an animal model of type I osteogenesis imperfecta. Audiol. Neurootol. 12, 334\u2013343 (2007).","journal-title":"Audiol. Neurootol."},{"key":"1282_CR88","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.15366","volume":"11","author":"F Ting","year":"2023","unstructured":"Ting, F. et al. The recombinant BMP-2 loaded silk fibroin microspheres improved the bone phenotype of mild osteogenesis imperfecta mice. PeerJ 11, e16191 (2023).","journal-title":"PeerJ"},{"key":"1282_CR89","doi-asserted-by":"crossref","first-page":"E8037","DOI":"10.1073\/pnas.1722200115","volume":"115","author":"C Gistelinck","year":"2018","unstructured":"Gistelinck, C. et al. Zebrafish type I collagen mutants faithfully recapitulate human type I collagenopathies. Proc. Natl Acad. Sci. USA 115, E8037\u2013E8046 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1282_CR90","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fendo.2020.00394","volume":"11","author":"L Claeys","year":"2020","unstructured":"Claeys, L., Bravenboer, N., Eekhoff, E. M. W. & Micha, D. Human fibroblasts as a model for the study of bone disorders. Front. Endocrinol. 11, 394 (2020).","journal-title":"Front. Endocrinol."},{"key":"1282_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18512-1","volume":"12","author":"FK Cayami","year":"2022","unstructured":"Cayami, F. K. et al. Osteogenic transdifferentiation of primary human fibroblasts to osteoblast-like cells with human platelet lysate. Sci. Rep. 12, 14686 (2022).","journal-title":"Sci. Rep."},{"key":"1282_CR92","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.3390\/ijms25063417","volume":"25","author":"L Claeys","year":"2024","unstructured":"Claeys, L. et al. In vitro modelling of osteogenesis imperfecta with patient-derived induced mesenchymal stem cells. Int. J. Mol. Sci. 25, 3417 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1282_CR93","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.scr.2019.101622","volume":"41","author":"BY Kim","year":"2019","unstructured":"Kim, B. Y., Ko, J. M., Park, M. H. & Koo, S. K. Generation of a patient-specific induced pluripotent stem cell line, KSCBi006-A, for osteogenesis imperfecta type I with the COL1A1, c.3162delT mutation. Stem Cell Res. 41, 101622 (2019).","journal-title":"Stem Cell Res."},{"key":"1282_CR94","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211510120","volume":"120","author":"SR Lamand\u00e9","year":"2023","unstructured":"Lamand\u00e9, S. R. et al. Modeling human skeletal development using human pluripotent stem cells. Proc. Natl Acad. Sci. USA 120, e2211510120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1282_CR95","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","volume":"183","author":"R Marom","year":"2020","unstructured":"Marom, R., Rabenhorst, B. M. & Morello, R. Management of endocrine disease: osteogenesis imperfecta: an update on clinical features and therapies. Eur. J. Endocrinol. 183, R95\u2013R106 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"1282_CR96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrendo.2010.141","volume":"6","author":"V Heath","year":"2010","unstructured":"Heath, V. Bone: promising combination therapy for children with osteogenesis imperfecta. Nat. Rev. Endocrinol. 6, 535 (2010).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1282_CR97","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1515\/jpem-2020-0071","volume":"33","author":"D Harada","year":"2020","unstructured":"Harada, D. et al. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment. J. Pediatr. Endocrinol. Metab. 33, 1391\u20131397 (2020).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"1282_CR98","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bonr.2018.04.009","volume":"8","author":"LJJ Scheres","year":"2018","unstructured":"Scheres, L. J. J. et al. Adults with osteogenesis imperfecta: clinical characteristics of 151 patients with a focus on bisphosphonate use and bone density measurements. Bone Rep. 8, 168\u2013172 (2018).","journal-title":"Bone Rep."},{"key":"1282_CR99","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1210\/clinem\/dgad035","volume":"108","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta. J. Clin. Endocrinol. Metab. 108, 1787\u20131796 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1282_CR100","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","volume":"24","author":"F Rauch","year":"2009","unstructured":"Rauch, F., Munns, C. F., Land, C., Cheung, M. & Glorieux, F. H. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J. Bone Miner. Res. 24, 1282\u20131289 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR101","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","volume":"21","author":"LA DiMeglio","year":"2006","unstructured":"DiMeglio, L. A. & Peacock, M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J. Bone Miner. Res. 21, 132\u2013140 (2006).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR102","first-page":"CD005088","volume":"10","author":"K Dwan","year":"2016","unstructured":"Dwan, K., Phillipi, C. A., Steiner, R. D. & Basel, D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst. Rev. 10, CD005088 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1282_CR103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","volume":"49","author":"T Bellido","year":"2011","unstructured":"Bellido, T. & Plotkin, L. I. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 49, 50\u201355 (2011).","journal-title":"Bone"},{"key":"1282_CR104","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler, O. et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J. Musculoskelet. Neuronal Interact. 12, 183\u2013188 (2012).","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"1282_CR105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/jcm7120479","volume":"7","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi, T. et al. Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis\u2014case series. J. Clin. Med. 7, 479 (2018).","journal-title":"J. Clin. Med."},{"key":"1282_CR106","volume":"14","author":"JD Hald","year":"2026","unstructured":"Hald, J. D. et al. Teriparatide plus zoledronic acid for osteogenesis imperfecta: a randomized clinical trial. JAMA 14, e266889 (2026).","journal-title":"JAMA"},{"key":"1282_CR107","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll, E. S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J. Clin. Invest. 124, 491\u2013498 (2014).","journal-title":"J. Clin. Invest."},{"key":"1282_CR108","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","volume":"93","author":"D Gatti","year":"2013","unstructured":"Gatti, D. et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif. Tissue Int. 93, 448\u2013452 (2013).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","volume":"14","author":"P Leali","year":"2017","unstructured":"Leali, P. Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin. Cases Miner. Bone Metab. 14, 153 (2017).","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"1282_CR110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","volume":"6","author":"M Uehara","year":"2022","unstructured":"Uehara, M. et al. Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report. Mod. Rheumatol. Case Rep. 6, 128\u2013133 (2022).","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"1282_CR111","first-page":"209","volume":"9","author":"A Dattagupta","year":"2023","unstructured":"Dattagupta, A. & Petak, S. Osteoporosis improved by romosozumab therapy in a patient with type I osteogenesis imperfecta. AACE Clin. Case Rep. 9, 209\u2013212 (2023).","journal-title":"AACE Clin. Case Rep."},{"key":"1282_CR112","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00198-024-07089-2","volume":"35","author":"T Kusakabe","year":"2024","unstructured":"Kusakabe, T. et al. Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta. Osteoporos. Int. 35, 1303\u20131304 (2024).","journal-title":"Osteoporos. Int."},{"key":"1282_CR113","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux, F. H. et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J. Bone Miner. Res. 32, 1496\u20131504 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR114","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux, F. H. et al. Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J. Bone Miner. Res. 39, 1215\u20131228 (2024).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR115","doi-asserted-by":"crossref","first-page":"bvae163.358","DOI":"10.1210\/jendso\/bvae163.358","volume":"8","author":"GS Gottesman","year":"2024","unstructured":"Gottesman, G. S. et al. 6820 assessing the efficacy and safety of setrusumab for osteogenesis imperfecta: updated phase 2 data from the phase 2\/3 Orbit study. J. Endocr. Soc. 8, bvae163.358 (2024).","journal-title":"J. Endocr. Soc."},{"key":"1282_CR116","unstructured":"Mereo BioPharma. Mereo BioPharma announces Phase 3 ORBIT and COSMIC results for setrusumab (UX143) in osteogenesis imperfecta. Mereo BioPharma https:\/\/www.mereobiopharma.com\/news\/phase-3-orbit-and-cosmic-results\/ (2025)."},{"key":"1282_CR117","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","volume":"20","author":"I Grafe","year":"2014","unstructured":"Grafe, I. et al. Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta. Nat. Med. 20, 670\u2013675 (2014).","journal-title":"Nat. Med."},{"key":"1282_CR118","volume":"132","author":"I-W Song","year":"2022","unstructured":"Song, I.-W. et al. Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta. J. Clin. Invest. 132, e152571 (2022).","journal-title":"J. Clin. Invest."},{"key":"1282_CR119","doi-asserted-by":"crossref","first-page":"101795","DOI":"10.1016\/j.bonr.2024.101795","volume":"22","author":"M Morita","year":"2024","unstructured":"Morita, M. et al. Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model. Bone Rep. 22, 101795 (2024).","journal-title":"Bone Rep."},{"key":"1282_CR120","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/jbmr\/zjae108","volume":"39","author":"M Rummler","year":"2024","unstructured":"Rummler, M. et al. Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab\u2014a sclerostin neutralizing antibody. J. Bone Miner. Res. 39, 1229\u20131239 (2024).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR121","unstructured":"Marini, J. C. & Dang Do, A. N. in Endotext (eds Feingold, K. R. et al.) (MDText.com, Inc., 2020)."},{"key":"1282_CR122","volume":"14","author":"RL Sagar","year":"2024","unstructured":"Sagar, R. L. et al. An exploratory open-label multicentre phase I\/II trial evaluating the safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe osteogenesis imperfecta in infants and fetuses: the BOOSTB4 trial protocol. BMJ Open 14, e079767 (2024).","journal-title":"BMJ Open"},{"key":"1282_CR123","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.265","volume":"11","author":"A Infante","year":"2021","unstructured":"Infante, A. et al. Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial. Clin. Transl. Med. 11, e265 (2021).","journal-title":"Clin. Transl. Med."},{"key":"1282_CR124","doi-asserted-by":"crossref","first-page":"102111","DOI":"10.1016\/j.omtn.2023.102111","volume":"35","author":"Y-S Yang","year":"2024","unstructured":"Yang, Y.-S. et al. AAV-based gene editing of type 1 collagen mutation to treat osteogenesis imperfecta. Mol. Ther. Nucleic Acids 35, 102111 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1282_CR125","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/jbmr.4549","volume":"37","author":"A Schindeler","year":"2020","unstructured":"Schindeler, A., Lee, L. R., O\u2019Donohue, A. K., Ginn, S. L. & Munns, C. F. Curative cell and gene therapy for osteogenesis imperfecta. J. Bone Miner. Res. 37, 826\u2013836 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"1282_CR126","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41434-025-00560-7","volume":"32","author":"K Kocsy","year":"2025","unstructured":"Kocsy, K. et al. Gene editing for collagen disorders: current advances and future perspectives. Gene Ther. 32, 676\u2013689 (2025).","journal-title":"Gene Ther."},{"key":"1282_CR127","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40618-023-02123-2","volume":"47","author":"X Lin","year":"2024","unstructured":"Lin, X. et al. Genotype\u2013phenotype relationship and comparison between eastern and western patients with osteogenesis imperfecta. J. Endocrinol. Invest. 47, 67\u201377 (2024).","journal-title":"J. Endocrinol. Invest."},{"key":"1282_CR128","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s00198-017-4143-8","volume":"28","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing. Osteoporos. Int. 28, 2985\u20132995 (2017).","journal-title":"Osteoporos. Int."},{"key":"1282_CR129","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00198-019-05076-6","volume":"30","author":"Y Ohata","year":"2019","unstructured":"Ohata, Y. et al. Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta. Osteoporos. Int. 30, 2333\u20132342 (2019).","journal-title":"Osteoporos. Int."},{"key":"1282_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0370-2","volume":"10","author":"HY Lin","year":"2015","unstructured":"Lin, H. Y. et al. Genotype and phenotype analysis of Taiwanese patients with osteogenesis imperfecta. Orphanet J. Rare Dis. 10, 152 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"1282_CR131","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1651-2227.1998.tb00920.x","volume":"87","author":"AM Lund","year":"1998","unstructured":"Lund, A. M. et al. Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr. 87, 1131\u20131137 (1998).","journal-title":"Acta Paediatr."},{"key":"1282_CR132","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1373\/clinchem.2006.083055","volume":"53","author":"T Cundy","year":"2007","unstructured":"Cundy, T., Horne, A., Bolland, M., Gamble, G. & Davidson, J. Bone formation markers in adults with mild osteogenesis imperfecta. Clin. Chem. 53, 1109\u20131114 (2007).","journal-title":"Clin. Chem."},{"key":"1282_CR133","unstructured":"Kocijan, R., Dinu, S. & Muschitz, C. in Biomarkers in Bone Disease (eds Patel, V. B. & Preedy, V. R.) 221\u2013237 (Springer, 2017)."},{"key":"1282_CR134","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/JMDH.S113483","volume":"10","author":"C Marr","year":"2017","unstructured":"Marr, C., Seasman, A. & Bishop, N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J. Multidiscip. Healthc. 10, 145\u2013155 (2017).","journal-title":"J. Multidiscip. Healthc."},{"key":"1282_CR135","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s00223-024-01305-1","volume":"115","author":"L Celli","year":"2024","unstructured":"Celli, L. et al. Adapting to adulthood: a review of transition strategies for osteogenesis imperfecta. Calcif. Tissue Int. 115, 960\u2013975 (2024).","journal-title":"Calcif. Tissue Int."},{"key":"1282_CR136","doi-asserted-by":"crossref","first-page":"869604","DOI":"10.3389\/fendo.2022.869604","volume":"13","author":"S Storoni","year":"2022","unstructured":"Storoni, S. et al. Prevalence and hospital admissions in patients with osteogenesis imperfecta in the Netherlands: a nationwide registry study. Front. Endocrinol. 13, 869604 (2022).","journal-title":"Front. Endocrinol."},{"key":"1282_CR137","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00264-016-3315-z","volume":"41","author":"HD Binh","year":"2017","unstructured":"Binh, H. D. et al. The clinical features of osteogenesis imperfecta in Vietnam. Int. Orthop. 41, 21\u201329 (2017).","journal-title":"Int. Orthop."},{"key":"1282_CR138","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00198-005-1905-5","volume":"16","author":"FE McKiernan","year":"2005","unstructured":"McKiernan, F. E. Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporos. Int. 16, 1698\u20131702 (2005).","journal-title":"Osteoporos. Int."},{"key":"1282_CR139","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.05.021","volume":"113","author":"AG Feehan","year":"2018","unstructured":"Feehan, A. G., Zacharin, M. R., Lim, A. S. & Simm, P. J. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood. Bone 113, 137\u2013143 (2018).","journal-title":"Bone"},{"key":"1282_CR140","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00198-017-4031-2","volume":"28","author":"G Bardai","year":"2017","unstructured":"Bardai, G. et al. Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta. Osteoporos. Int. 28, 2095\u20132101 (2017).","journal-title":"Osteoporos. Int."},{"key":"1282_CR141","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/humu.22368","volume":"34","author":"MM Weiss","year":"2013","unstructured":"Weiss, M. M. et al. Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories. Hum. Mutat. 34, 1313\u20131321 (2013).","journal-title":"Hum. Mutat."},{"key":"1282_CR142","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/cge.70003","volume":"108","author":"H Sait","year":"2025","unstructured":"Sait, H. et al. Molecular and clinical landscape of osteogenesis imperfecta: unraveling autosomal recessive forms, therapeutic outcomes, and bone mineral density in carriers. Clin. Genet. 108, 684\u2013695 (2025).","journal-title":"Clin. Genet."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01282-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01282-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01282-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:02:53Z","timestamp":1791547373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-026-01282-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1038\/s41574-026-01282-5","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"1 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}